1. de Barros PP, Rossoni RD, de Souza CM, Scorzoni L, Fenley JC, Junqueira JC. Candida biofilms: an update on developmental mechanisms and therapeutic challenges. Mycopathologia 2020; 185: 415-424.
2. Zarei Mahmoudabadi A, Zarrin M, Kiasat N. Biofilm formation and susceptibility to amphotericin B and fluconazole in Candida albicans. Jundishapur J Microbiol 2014; 7(7): e17105.
3. Tobudic S, Kratzer C, Lassnigg A, Presterl E. Antifungal susceptibility of Candida albicans in biofilms. Mycoses 2012; 55: 199-204.
4. Ferreira JA, Carr JH, Starling CE, de Resende MA, Donlan RM. Biofilm formation and effect of caspofungin on biofilm structure of Candida species bloodstream isolates. Antimicrob Agents Chemother 2009; 53: 4377-4384.
5. Silva S, Rodrigues CF, Araujo D, Rodrigues ME, Henriques M. Candida species biofilms' antifungal resistance. J Fungi (Basel) 2017; 3: 8.
6. Prazynska M, Bogiel T, Gospodarek-Komkowska E. In vitro activity of micafungin against biofilms of Candida albicans, Candida glabrata, and Candida parapsilosis at different stages of maturation. Folia Microbiol (Praha) 2018; 63: 209-216.
7. Betts RF, Nucci M, Talwar D, Gareca M, Queiroz-Telles F, Bedimo RJ, et al. A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis 2009; 48: 1676-1684.
8. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-2029.
9. Gharaghani M, Hivary S, Taghipour S, Zarei-Mahmoudabadi A. Luliconazole, a highly effective imidazole, against Fusarium species complexes. Med Microbiol Immunol 2020; 209: 603-612.
10. Gharaghani M, Taghipour S, Zarei Mahmoudabadi A. Molecular identification, biofilm formation and antifungal susceptibility of Rhodotorula spp. Mol Biol Rep 2020; 47: 8903-8909.
11. Moslem M, Mahmoudabadi AZ. The high efficacy of luliconazole against environmental and otomycosis Aspergillus flavus strains. Iran J Microbiol 2020; 12: 170-176.
12. Taghipour S, Kiasat N, Shafiei S, Halvaeezadeh M, Rezaei-Matehkolaei A, Zarei Mahmoudabadi A. Luliconazole, a new antifungal against Candida species isolated from different sources. J Mycol Med 2018; 28: 374-378.
13. Watanabe R, Huruta H, Ueno Y, Nukada T, Niwa H, Shinyashiki N, et al. Antifungal susceptibility of dermatophytes from racehorses in Japan. Vet Dermatol 2021; 32: 474-e129.
14. Kiasat N, Rezaei-Matehkolaei A, Mahmoudabadi AZ. Microsatellite typing and antifungal susceptibility of Candida glabrata strains isolated from patients with Candida vaginitis. Front Microbiol 2019; 10: 1678.
15. Gharaghani M, Rezaei-Matehkolaei A, Hardani AK, Zarei Mahmoudabadi A. Pediatric candiduria, epidemiology, genotype distribution and virulence factors of Candida albicans. Microb Pathog 2021; 160: 105173.
16. Jafarian H, Gharaghani M, Seyedian SS, Mahmoudabadi AZ. Genotyping, antifungal susceptibility, enzymatic activity, and phenotypic variation in Candida albicans from esophageal candidiasis. J Clin Lab Anal 2021; 35(7): e23826.
17. Kianifar S, Rezaei-Matehkolaei A, Zarei-Mahmoudabadi A. Genotypes analysis of Candida albicans species complex from healthy individual saliva in Ahvaz, Iran. Lett Appl Microbiol 2022; 75: 831-835.
18. CLSI (2017). Reference method for broth dilution antifungal susceptibility testing of yeasts; CLSI standard M27. 4th ed. Wayne, PA: Clinical and Laboratory Standards Institute. https://clsi.org/shop/standards/m27/
19. Tulasidas S, Rao P, Bhat S, Manipura R. A study on biofilm production and antifungal drug resistance among Candida species from vulvovaginal and bloodstream infections. Infect Drug Resist 2018; 11: 2443-2448.
20. Marcos-Zambrano LJ, Escribano P, Bouza E, Guinea J. Susceptibility of Candida albicans biofilms to caspofungin and anidulafungin is not affected by metabolic activity or biomass production. Med Mycol 2016; 54: 155-161.
21. Pereira R, Dos Santos Fontenelle RO, de Brito EHS, de Morais SM. Biofilm of Candida albicans: formation, regulation and resistance. J Appl Microbiol 2021; 131: 11-22.
22. Guembe M, Cruces R, Pelaez T, Munoz P, Bouza E; GEIDI study group. Assessment of biofilm production in Candida isolates according to species and origin of infection. Enferm Infecc Microbiol Clin 2017; 35: 37-40.
23. CLSI (2012). M27-S4: Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Fourth Informational Supplement. Clinical and Laboratory Standards Institute, Annapolis Junction.
https://www.scirp.org/reference/referencespapers?referenceid=3102472
24. de Aquino Lemos J, Costa CR, de Araujo CR, Souza LK, Silva Mdo R. Susceptibility testing of Candida albicans isolated from oropharyngeal mucosa of HIV(+) patients to fluconazole, amphotericin B and Caspofungin. killing kinetics of caspofungin and amphotericin B against fluconazole resistant and susceptible isolates. Braz J Microbiol 2009; 40: 163-169.
25. Shokohi T, Badali H, Amirrajab N, Ataollahi MR, Kouhpayeh SA, Afsarian MH. In vitro activity of five antifungal agents against Candida albicans isolates, Sari, Iran. Curr Med Mycol 2016; 2: 34-39.
26. Yenisehirli G, Bulut N, Yenisehirli A, Bulut Y. In vitro susceptibilities of Candida albicans isolates to antifungal agents in Tokat, Turkey. Jundishapur J Microbiol 2015; 8(9): e28057.
27. Koga H, Tsuji Y, Inoue K, Kanai K, Majima T, Kasai T, et al. In vitro antifungal activity of luliconazole against clinical isolates from patients with dermatomycoses. J Infect Chemother 2006; 12: 163-165.
28. Shokoohi G, Sefidmazgi RR, Etehadnezhad M, Ahmadi B, Javidnia J, Nouripour-Sisakht S, et al. In vitro antifungal activity of luliconazole, efinaconazole, and nine comparators against Aspergillus and Candida strains isolated from otomycosis. Jundishapur J Microbiol 2021; 14(4): e115902.
29. Gharaghani M, Rezaei‐Matehkolaei A, Hardani A, Zarei Mahmoudabadi A. Genotypic diversity and antifungal susceptibility pattern of Candida albicans species isolated from hospitalized paediatric patients with urinary tract infection in Iran. J Appl Microbiol 2021; 131: 1017-1027.
30. Zomorodian K, Bandegani A, Mirhendi H, Pakshir K, Alinejhad N, Poostforoush Fard A. In vitro susceptibility and trailing growth effect of clinical isolates of Candida species to azole drugs. Jundishapur J Microbiol 2016; 9(2): e28666.